Michael M F Lahn

Affiliations

Formerly Eli Lilly and Company, Indianapolis, IN, USA.

Publications (2)

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.

Investigational new drugs

Avec: Masafumi Ikeda , Manabu Morimoto , Masaomi Tajimi , Koichi Inoue , Karim A Benhadji , Daisuke Sakai

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.

Cancer chemotherapy and pharmacology

Avec: Davide Melisi , Rocio Garcia-Carbonero , Teresa Macarulla , Denis Pezet , Gael Deplanque , Martin Fuchs , Jorg Trojan , Mark Kozloff , Francesca Simionato , Ann Cleverly , Claire Smith , Shuaicheng Wang , Michael Man , Kyla E Driscoll , Shawn T Estrem , Karim A Benhadji , Josep Tabernero

Réseau de co-auteurs

Karim A Benhadji 2 collaborations

Masafumi Ikeda 1 collaboration

Manabu Morimoto 1 collaboration

Masaomi Tajimi 1 collaboration

Koichi Inoue 1 collaboration

Daisuke Sakai 1 collaboration

Davide Melisi 1 collaboration

Rocio Garcia-Carbonero 1 collaboration

Teresa Macarulla 1 collaboration

Denis Pezet 1 collaboration

Gael Deplanque 1 collaboration

Martin Fuchs 1 collaboration

Jorg Trojan 1 collaboration

Mark Kozloff 1 collaboration

Francesca Simionato 1 collaboration

Ann Cleverly 1 collaboration

Claire Smith 1 collaboration

Shuaicheng Wang 1 collaboration

Michael Man 1 collaboration

Kyla E Driscoll 1 collaboration

Shawn T Estrem 1 collaboration

Josep Tabernero 1 collaboration